Thestocktraderhubzee Posted - 04/23/24

WATCHLIST APR 23 2024.. $SLB Morgan Stanley Maintains Overweight on Schlumberger, Maintains $65 Price Target $PHVS Morgan Stanley Maintains Overweight on Pharvaris, Maintains $34 Price Target $KBR Citigroup Maintains Buy on KBR, Raises Price Target to $72 $ACM Citigroup Maintains Buy on AECOM, Raises Price Target to $116 $WTFC Citigroup Maintains Buy on Wintrust Finl, Lowers Price Target to $113

DonCorleone77 Posted - 04/12/24

$PHVS Pharvaris files automatic mixed securities shelf

DonCorleone77 Posted - 04/10/24

$PHVS 2 of 2 - Pharvaris reports Q4 EPS (EUR 0.74) vs. (EUR 1.16) last year ....We are pleased with the HAE community's excitement in RAPIDe-3, which is enrolling as planned; we will provide the anticipated timing of topline data as enrollment progresses and data is accumulated. Receipt of the Innovation Passport designation for deucrictibant in the UK reflects regulatory recognition of deucrictibant's innovation for better treatment options for people living with HAE."

DonCorleone77 Posted - 04/10/24

$PHVS 1 of 2 - Pharvaris reports Q4 EPS (EUR 0.74) vs. (EUR 1.16) last year Cash and cash equivalents were approximately EUR 391M as of December 31, 2023, compared to approximately EUR 162M for December 31, 2022. "2024 is off to a strong start, supported by the incredible momentum we built in an impressive 2023-driven by a second positive data readout of deucrictibant that was validated by the support of our investors," said Berndt Modig, Chief Executive Officer of Pharvaris. "At the start of the year, the lift of the remaining hold on the prophylaxis program in the U.S. allowed us to progress with the global Phase 3 clinical development plans for deucrictibant for prevention of HAE attacks. As we move toward the initiation of CHAPTER-3, we hope to realize the promise of the proof-of-concept CHAPTER-1 data, which support deucrictibant's potential to be a best-in-class oral prophylactic therapy....

Stock_Titan Posted - 04/10/24

$PHVS Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update https://www.stocktitan.net/news/PHVS/pharvaris-reports-fourth-quarter-and-full-year-2023-financial-zfeemq8d0c8e.html

CandlesBACKEDSECURITIES Posted - 04/04/24

$PHVS $BCRX who from JMP Securities is covering Pharvaris?? Liisa Bayko? What does she think

CandlesBACKEDSECURITIES Posted - 04/04/24

$PHVS $BCRX so this is the company that could bankrupt BCRX? Superior oral HAE product???

Stock_Titan Posted - 04/04/24

$PHVS Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference https://www.stocktitan.net/news/PHVS/pharvaris-to-present-deucrictibant-clinical-data-at-the-ciic-spring-omq0ig66fd0i.html

DailyStocksPicks Posted - 03/24/24

Acelyrin ($SLRN): Acelyrin’s stock is perceived as oversold due to the divergence between its clinical advancements, institutional support, and analysts' optimistic forecasts versus its recent stock performance. Despite facing downward pressure, the company’s engagement in critical clinical trials and backing from notable institutional investors suggest an underappreciation of its value and potential, especially when considering its innovative pipeline in addressing unmet medical needs. $TYRA, $ZYME, $PHVS, $WVE For More Details: https://youtu.be/yeL_bMBSsNQ

briefingcom Posted - 03/18/24

$PHVS: Pharvaris N.V. announces phase 3 clinical study design for recently initiated RAPIDe-3 Study, and presents quality-of-life improvement and caregiver behavior data at Two Recent HAE Congresses https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240318065141PHVS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 03/18/24

$PHVS Pharvaris initiates RAPIDe-3, the Phase 3 clinical trial The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks.

RAPIDTRADX Posted - 03/18/24

$PHVS 👀

Stock_Titan Posted - 03/18/24

$PHVS Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses https://www.stocktitan.net/news/PHVS/pharvaris-announces-phase-3-clinical-study-design-for-recently-afzn0nzpd2c3.html

DonCorleone77 Posted - 03/06/24

$PHVS Pharvaris files to sell 5.55M ordinary shares for holders

Stock_Titan Posted - 03/06/24

$PHVS Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses https://www.stocktitan.net/news/PHVS/pharvaris-to-present-deucrictibant-clinical-data-at-upcoming-9oopipoz3vve.html

Stock_Titan Posted - 03/05/24

$PHVS Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 https://www.stocktitan.net/news/PHVS/pharvaris-to-participate-in-the-leerink-global-biopharma-conference-rum2jtwk1ejv.html

TickerDD_com Posted - 03/04/24

From 2/28/2024, looking back across 22 Month-Ends for PHVS, Percentage Change of Average Monthly Price had More Positives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $PHVS #PHVS #PHVSStock #TickerDD #PHVSPrice https://www.youtube.com/watch?v=7JTyf1GL8LI

swingingtech Posted - 02/29/24

$PHVS $SPY https://wallstreetwaves.com/pharvaris-enters-oversold-territory-phvs/

Project_Profit Posted - 02/26/24

$BCRX They were very specific on what they expected: -Mid 80Ms for Q1 rev -321 new subs for 24' -71.5% Are now on paid- from free (goal of 85 by 29') Solid road map and loved the reiterated "why would anybody switch to another prophylactic when they are fully controlled on a once a day pill" Cowen cam out today w a reiterated BUY w $20 target and stated the same thing. $PHVS is mute essentially.

Project_Profit Posted - 02/23/24

@Del_Gue yeah, like talk about a headwind for the competition coming on line. $PHVS doesn't stand a chance and their going to burn a fortune running a p3 trial then they have to apply for approval world wide. They should about face like leadership did with FOP

briefingcom Posted - 02/22/24

$PHVS (+15%): Positive results from CHAPTER-1 phase 2 study of deucrictibant for the prophylactic treatment of HAE attacks to be presented at AAAAI 2024 Annual Meeting

OpenOutcrier Posted - 02/22/24

$PHVS (+0.7% pre) Pharvaris reports breakthrough in HAE attack prevention - inv https://ooc.bz/l/25673

Stock_Titan Posted - 02/22/24

$PHVS Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting https://www.stocktitan.net/news/PHVS/positive-results-from-chapter-1-phase-2-study-of-deucrictibant-for-u5vjnmoy4imc.html

Stock_Titan Posted - 02/16/24

$PHVS Pharvaris Announces Extraordinary Meeting of Shareholders https://www.stocktitan.net/news/PHVS/pharvaris-announces-extraordinary-meeting-of-rd348qxpa9tc.html

Thestocktraderhubzee Posted - 02/15/24

WATCHLIST FEB 15 2024 $PHVS JMP Securities Reiterates Market Outperform on Pharvaris, Maintains $49 Price Target $HOOD JMP Securities Maintains Market Outperform on Robinhood Markets, Raises Price Target to $25 $BLNK Needham Reiterates Buy on Blink Charging, Maintains $7 Price Target $UNCY Noble Capital Markets Initiates Coverage On Unicycive Therapeutics with Outperform Rating, Announces Price Target of $6 $ROIV HC Wainwright & Co. Maintains Buy on Roivant Sciences, Lowers Price Target to $17

Project_Profit Posted - 02/06/24

$BCRX seeing some posts about PhartVirus $PHVS and some great points-Primarily, why would these pxs, who are completely controlled... Switch. Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0 attacks per month in 20 of 24 months And I also like that BCRX has a solid team in place world wide with great tools such as the image below.

Doozio Posted - 02/05/24

$phvs wen stonks 👀 like this n they just need a lil 🧠 nudge in 🧠⏰ to get in $rytm $xbi is in its initial consolidation. Don’t get it $twst d. Or do.

Doozio Posted - 01/26/24

$PHVS like in week FOUR of 2020FOUR during 🧠⏰. Explosive 👀

Skidude69 Posted - 01/25/24

$PHVS love my long position here

STCKPRO Posted - 01/24/24

$PHVS NEW ARTICLE : Buy Rating Affirmed for Pharvaris with Increased Price Target Following FDA Regulatory Advances https://stck.pro/news/PHVS/73637343/